No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

HeartVista Receives FDA 510(k) Clearance to Deliver One Click MRI™ on Siemens Healthineers MRI Scanners

New AHA and ACC Guidelines, Making Cardiac MRI a Class I Recommendation for Chest Pain, Will Increase CMR Use to Widely Impact the Practice of Cardiology

Editor: What To Know

  • On the basis of the diagnostic accuracy of cardiac MRI for coronary artery disease and myocarditis, the test is now recommended as a Class I recommendation for the evaluation of chest pain,” said Bob S.
  • Beyond compatibility with Siemens Healthineers MRI scanners, the newly FDA-cleared One Click MRI™ software includes product-wide speed and scan accuracy enhancements, as well new real-time automated analysis of regional wall motion as part of cardiac function assessment, new registration of perfusion images for easier visual defect detection, enhanced T1-mapping for cardiomyopathy analysis, and dedicated septal T1-mapping for myocarditis.
  • The team dedicated over 5,000 hours to the clearance process during a pandemic, and evaluated our software by scanning a broad array of patients and volunteers on multiple MRI machines across three countries,” said Itamar Kandel, CEO of HeartVista.

HeartVista, a pioneer in AI-assisted MRI solutions, today announced it has received 510(k) Clearance from the U.S. Food and Drug Administration, to deliver its AI-assisted One Click MRI™ acquisition software on Siemens Healthineers MRI scanners.

Despite many advantages, the use of cardiac MRI, also known as cardiac magnetic resonance (CMR), has been largely limited due to a lack of trained technologists, high cost, long scan time and difficulty of use. With HeartVista’s AI-assisted solutions, CMR exams on Siemens’ MRI scanners are simpler, significantly faster, and achieve more consistent results.

Siemens is a global leader in Magnetic Resonance (MR), and clinical decision-making. One Click MRI™ clearance on Siemens Healthineers MRI scanners advances HeartVista’s mission of improving and increasing patient access to real-time MRI imaging, to enable better treatment decisions for physicians.

Beyond compatibility with Siemens Healthineers MRI scanners, the newly FDA-cleared One Click MRI™ software includes product-wide speed and scan accuracy enhancements, as well new real-time automated analysis of regional wall motion as part of cardiac function assessment, new registration of perfusion images for easier visual defect detection, enhanced T1-mapping for cardiomyopathy analysis, and dedicated septal T1-mapping for myocarditis.

“We’re excited to receive FDA 510(k) Clearance for One-Click MRI™ with Siemens scanners, which positions us as a multi-vendor platform for global CMR deployment. This groundbreaking achievement was a result of our hardworking R&D team’s efforts. The team dedicated over 5,000 hours to the clearance process during a pandemic, and evaluated our software by scanning a broad array of patients and volunteers on multiple MRI machines across three countries,” said Itamar Kandel, CEO of HeartVista. “By expanding our cardiac MRI compatibility to include Siemens Healthineers’ scanners, some of the world’s most popular MRI machines, we have taken a major leap forward to enable cardiac MRI access for all.”

The American Heart Association (AHA), the American College of Cardiology (ACC), and other groups issued new guidelines, making cardiac magnetic resonance (CMR) a Class I recommendation as a front-line testing strategy for the diagnosis of chest pain.

“Chest pain is one of the most important and most common symptoms our patients complain about. On the basis of the diagnostic accuracy of cardiac MRI for coronary artery disease and myocarditis, the test is now recommended as a Class I recommendation for the evaluation of chest pain,” said Bob S. Hu, M.D., HeartVista’s Chief Medical Officer. “This recent FDA 510(k) Clearance will enable increased access to HeartVista’s AI-assisted One Click MRI™ acquisition software, enabling physicians to make better treatment decisions for patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy